University of Chile

FRAXA Drug Validation Initiative (FRAXA-DVI)

FRAXA Research Foundation 2011 Grants • 2012 Grants • 2013 Grants • 2014 Grants • 2015 Grants • 2016 Grants • 2017 Grants • 2018 Grants • 2019 Grants • 2020 Grants • 2021 Grants • Biomarkers • Carullo, Paulina • Cogram, Patricia • Current Research Grants • Deacon, Robert • Drug Repurposing • FLENI Foundation • Research Resources • University of Chile • University of Oxford May 6, 2021May 6, 2021BPN14770, drug repurposing, EEG, FRAXA-DVI, Healx, Neuren Pharmaceuticals, NIH, Ovid Therapeutics, PDE4, Tetra Therapeutics, trofinetide

The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing of potential Fragile X treatments. FRAXA-DVI uses in-vitro systems, behavior batteries, and gene expression and peripheral biomarker platforms to validate investigational new drugs and repurposed available compounds in Fragile X syndrome (FXS).

In Vitro Coherent Network Activity

FRAXA Research Foundation 2011 Grants • 2012 Grants • Bacigalupo, Juan • Completed Research Grants • Disease Mechanisms • University of Chile February 22, 2012April 25, 2018

With a $90,000 grant from FRAXA Research Foundation from 2011-2012, Dr. Juan Bacigalupo at the University of Chile studied the abnormal network dynamics of the brain in Fragile X mice to provide information for future therapeutic drug screening.